inner-banner-bg

International Journal of Cancer Research & Therapy(IJCRT)

ISSN: 2476-2377 | DOI: 10.33140/IJCRT

Impact Factor: 1.3

Pre operative Early Hormonotherapy the New Gold Standard for Operable Luminal Breast Cancer

Abstract

Vasco Fonseca, Zacharoula Sidiropoulou

Even though it is not yet a universally accepted, in our view, the best clinical practice in the case of operable luminal breast cancer is to begin systemic neoadjuvant hormonotherapy (HT) immediately after histologic diagnosis for the majority of patients. This strategy does not apply to patients with an indication for neoadjuvant chemotherapy.

PDF